CUSIP: 86627R102
Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Stock
-
Total 13F shares
-
2,882,824
-
Share change
-
-62,187
-
Total reported value
-
$3,315,000
-
Price per share
-
$1.15
-
Number of holders
-
10
-
Value change
-
-$169,873
-
Number of buys
-
5
-
Number of sells
-
6
Quarterly Holders Quick Answers
What is CUSIP 86627R102?
CUSIP 86627R102 identifies SMMT - SUMMIT THERAPEUTICS INC COM - Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2019
-
Previous quarter:
Q3 2018
Recent filing periods for CUSIP 86627R102:
Institutional Holders of SUMMIT THERAPEUTICS INC COM - Stock (SMMT) as of Q4 2018
As of 31 Dec 2018,
SUMMIT THERAPEUTICS INC COM - Stock (SMMT) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,882,824 shares.
The largest 10 holders included
LANSDOWNE PARTNERS (UK) LLP, Point72 Asset Management, L.P., Polar Capital LLP, MORGAN STANLEY, ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, SeaCrest Wealth Management, LLC, and GROUP ONE TRADING, L.P..
This page lists
10
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.